Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sabine Neser"'
Autor:
Sabine Neser, Antje Haas, Ralph Naumann, Erika Kettner, Robert Rohrberg, Kathrin Haifa Al-Ali, Ursula Haak, Michael Herold, Christian Klinkenstein, Astrid Franke, Mathias Freund, Gottfried Dölken, Ulrich Mey, Ullrich von Grünhagen, Michael Aβmann, Klaus Höffken, Stefanie Srock, Wolfgang Knauf, Thomas Ittel, Andreas Neubauer
Publikováno v:
Journal of Clinical Oncology. 25:1986-1992
Purpose Rituximab has been shown to be active in follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. We conducted a randomized trial comparing mitoxantrone, chlorambucil, and prednisolone (MCP) chemotherapy plus rituxi
Autor:
Michael Assmann, Thomas Kiefer, Antje Haas, Malte Leithäuser, Charles S. Rabkin, Frank Schüler, Sabine Neser, Carsten Hirt, Michael Herold, Cornelia Schwenke, Stefanie Srock, Gottfried Dölken, Dietger Niederwieser, Klaus Dachselt, Robert Rohrberg
Publikováno v:
British journal of haematology. 141(5)
This study of first-line treatment in advanced-stage follicular lymphoma patients analysed the effects of MCP (mitoxantrone, chlorambucil and prednisolone) chemotherapy alone or in combination with rituximab (R-MCP) on circulating lymphoma cells (CLC
Autor:
Michael Herold, Kathrin H. Al Ali, Andreas Neubauer, Stephanie Srock, Antje Haas, Mathias Freund, Erika Kettner, Ralph Naumann, Thomas Ittel, Martin Mohren, Klaus Hoeffken, Sabine Neser, Robert Rohrberg, Thomas Fietz, Gottfried Doelken
Publikováno v:
Blood. 110:4474-4474
Introduction: Rituximab plus chemotherapy has been proved to be the standard in treating advanced follicular lymphoma. However in mantle cell lymphoma (MCL) the results are still controversial. Methods: In a prospective randomised trial (OSHO#39) we
Autor:
Sabine Neser, Andreas Neubauer, Stephanie Srock, Astrid Franke, Ralph Naumann, Gottfried Doelken, Michael Herold, Thomas Ittel, Antje Haas, Thomas Fietz, Erika Kettner, Robert Rohrberg, Mathias Freund, Klaus Hoeffken, Kathrin H. Al Ali
Publikováno v:
Blood. 108:484-484
Introduction: Rituximab plus chemotherapy has been proved to be the gold - standard in treating advanced follicular lymphoma. Here we report the 4-year-follow-up data of our phase III trial comparing MCP - chemotherapy vs rituximab + MCP both followe
Autor:
Dietger Niederwieser, Michael Herold, Thomas Kiefer, Charles S. Rabkin, Gottfried Dölken, Michael Assmann, Carsten Hirt, Klaus Dachselt, Frank Schueler, Antje Haas, Sabine Neser, Malte Leithaeuser
Publikováno v:
Blood. 108:2757-2757
In a prospective multicenter phase III trial (M 39023) advanced stage follicular lymphoma (FL) patients were randomized to receive eight cycles of MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy alone or in combination with rituximab (R-M
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli
Autor:
Ursula Haak, Astrid Franke, Ullrich Mey, Peter Richter, Rita Pasold, Stefanie Srock, Volker Lakner, Franz-Adolph Hoffmann, Sabine Neser, Gottfried Dölken, Thomas Ittel, Helga Schwenke, Ralph Naumann, Thomas Fietz, Andreas Neubauer, Michael Herold, Robert Rohrberg, Erika Kettner, Norbert Grobe, Mathias Freund, Dietger Niederwieser, Michael Assmann, Christian Klinkenstein, Dorothee Bleyl, Heiner Wolf, Detlev Hähling, Ullrich von Gruenhagen, Michael R. Clemens, H.-H. Wolf, Klaus Dachselt, Sabine Hahnfeld, Henning Eschenburg, Klaus Hoeffken
Publikováno v:
Blood. 104:584-584
Rituximab proved to be effective in relapsed and refractory indolent NHL as a single agent and generated impressive results in phase II studies in combination with chemotherapy. In a prospective randomized trial we compared the efficacy and toxicity